Nanosonics Ltd (ASX: NAN) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Nanosonics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.26 billion
P/E Ratio 62.33
Dividend Yield 0.00%
Shares Outstanding 303.35 million
Earnings per share 0.067
Dividend per share N/A
Year To Date Return 5.04%
Earnings Yield 1.60%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Nanosonics Ltd (ASX: NAN)
    Latest News

    a woman
    ⏸️ Investing

    Why MesoBLAST limited is rocketing higher on FDA approval

    The Mesoblast limited (ASX:MSB) share price is responding to FDA recognition of its aGVHD drug.

    Read more »

    a woman
    ⏸️ Investing

    Here are 2 healthcare shares at the top of my shopping list

    Which healthcare shares should you buy today? I think the Ramsay Health Care Limited (ASX:RHC) share price is one of…

    Read more »

    a woman
    ⏸️ Investing

    6 growth shares I'm watching in 2017

    At these prices, I think Class Ltd (ASX:CL1) shares, Hansen Technologies Limited (ASX:HSN) shares, Nanosonics Ltd (ASX:NAN) shares, Praemium Ltd…

    Read more »

    a woman
    ⏸️ Investing

    3 growth stocks I'd buy with $5,000 today

    Healthscope Ltd (ASX:HSO) and Nanosonics Ltd. (ASX:NAN) are 2 of 3 great growth stocks to buy today.

    Read more »

    a woman
    ⏸️ Investing

    Why the Resapp Health Ltd share price is sliding today

    The Resapp Health Ltd (ASX:RAP) share price may be heading lower in 2017.

    Read more »

    a woman
    ⏸️ Investing

    ASX preview on Wednesday: 7 shares you need to watch today

    The SBM share price, as well as Northern Star Resources, were both hammered on Tuesday

    Read more »

    a woman
    ⏸️ Investing

    Earnings Wrap on Tuesday: 11 shares you should have been watching

    The WOR share price skyrocketed today following a takeover offer

    Read more »

    a woman
    ⏸️ Investing

    Earnings Wrap on Monday: 12 shares you should have been watching

    The QBE share price shed its earlier gains but still finished the session in the black

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares have started the week with a BANG

    The Aconex Ltd (ASX:ACX) share price is one of four to have started the week with a bang. Here’s why…

    Read more »

    a woman
    ⏸️ Investing

    3 blistering growth shares for 2017

    Class Ltd (ASX:CL1), Nanosonics Ltd. (ASX:NAN) and Webjet Limited (ASX:WEB) are looking good after their results.

    Read more »

    a woman
    ⏸️ Investing

    Earnings Wrap on Thursday: 16 shares you should have been watching

    The SKT share price was slammed today, but the QAN share price rose strongly

    Read more »

    a woman
    ⏸️ Investing

    Earnings Wrap on Tuesday: 9 shares you should have been watching

    The ACX share price was under pressure again on Tuesday

    Read more »

    Frequently Asked Questions

    No, Nanosonics Ltd does not pay dividends at this stage.

    Nanosonics Ltd listed on the ASX on 17 May 2007.

    NAN ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Nanosonics Ltd

    Nanosonics Ltd (ASX: NAN) is an Australian healthcare company specialising in infection prevention.

    The company has developed and commercialised an automated disinfection technology, the trophon device. Nanosonics says it represents the first major innovation in high-level disinfection for ultrasound probes in more than two decades and is fast becoming the global standard of care for ultrasound probe disinfection. The company also manufactures and distributes other related technologies.

    Nanosonics is based in Sydney with sales offices in the US and Europe.

    NAN Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    13 Jan 2026 $4.17 $0.06 1.46% 183,551 $4.10 $4.20 $4.10
    12 Jan 2026 $4.11 $-0.03 -0.72% 205,711 $4.14 $4.22 $4.09
    09 Jan 2026 $4.14 $-0.03 -0.72% 161,473 $4.15 $4.23 $4.11
    08 Jan 2026 $4.17 $0.09 2.21% 292,928 $4.07 $4.18 $4.04
    07 Jan 2026 $4.08 $0.15 3.82% 261,074 $3.92 $4.08 $3.92
    06 Jan 2026 $3.93 $-0.01 -0.25% 219,411 $3.90 $3.96 $3.90
    05 Jan 2026 $3.94 $0.02 0.51% 256,469 $3.92 $3.95 $3.90
    02 Jan 2026 $3.92 $-0.05 -1.26% 185,469 $3.94 $4.02 $3.92
    31 Dec 2025 $3.97 $-0.01 -0.25% 195,929 $3.92 $4.02 $3.92
    30 Dec 2025 $3.98 $0.00 0.00% 181,692 $4.01 $4.02 $3.94
    29 Dec 2025 $3.98 $0.00 0.00% 235,989 $4.00 $4.03 $3.95
    24 Dec 2025 $3.98 $-0.08 -1.97% 103,671 $4.06 $4.06 $3.97
    23 Dec 2025 $4.06 $0.01 0.25% 156,330 $4.04 $4.07 $4.01
    22 Dec 2025 $4.05 $0.00 0.00% 133,931 $4.10 $4.11 $4.04
    19 Dec 2025 $4.05 $-0.03 -0.74% 452,244 $4.12 $4.12 $4.02
    18 Dec 2025 $4.08 $0.02 0.49% 486,972 $4.09 $4.11 $4.01
    17 Dec 2025 $4.06 $0.01 0.25% 225,493 $4.07 $4.10 $4.05
    16 Dec 2025 $4.05 $-0.06 -1.46% 391,034 $4.09 $4.10 $4.03

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    18 Dec 2025 Michael Kavanagh Issued 405,184 $1,653,150
    Issue of securities. 18,58,192 Rights
    11 Dec 2025 Michael Kavanagh Issued 59,233 $257,071
    Issue of securities. 1,453,008 Rights
    04 Dec 2025 Michael Kavanagh Exercise 66,380 $274,813
    Conversion of securities. 13,93,775 rights
    04 Dec 2025 Michael Kavanagh Buy 66,380 $274,813
    Conversion of securities.
    23 Sep 2025 Michael Kavanagh Buy 109,685 $462,870
    Conversion of securities.
    23 Sep 2025 Michael Kavanagh Exercise 109,685 $462,870
    Conversion of securities. 1,460,155 - Rights
    17 Sep 2025 Gerard Dalbosco Buy 12,558 $51,231
    On-market trade. Average $4.08 per share, as per announcement
    01 May 2025 Michael Kavanagh Sell 50,000 $232,489
    On-market trade. ex brokerage
    01 May 2025 Michael Kavanagh Transfer 673,360 $3,285,996
    As advised by the company. In addition, 673,360 Ordinary Shares
    previously held indirectly in the Nanosonics
    Employee Equity Trust are now held directly
    by Mr Kavanagh.
    01 May 2025 Michael Kavanagh Transfer 673,360 $3,285,996
    As advised by the company. In addition, 673,360 Ordinary Shares
    previously held indirectly in the Nanosonics
    Employee Equity Trust are now held directly
    by Mr Kavanagh.
    30 Apr 2025 Michael Kavanagh Sell 50,000 $232,489
    On-market trade.
    11 Mar 2025 Gerard Dalbosco Buy 7,442 $32,372
    On-market trade.
    07 Mar 2025 Gerard Dalbosco Buy 20,000 $87,139
    On-market trade. Approximately
    03 Mar 2025 Tracey Batten Buy 15,715 $73,941
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Larry Marshall Non-Executive Director Oct 2023
    Dr Marshall is a technology innovator, physicist and business leader. Until July 2023, Dr Marshall was Chief Executive of CSIRO for eight and a half years. During his 26 years in the US, Dr Marshall co-founded six companies in a range of markets including medical device which went public. Over the past 30 years, he has served as CEO/ MD of six companies, and Chairman of four. He was MD, then co-Chairman of Arasor which he took public in 2006. In 2007, Dr Marshall became MD of Southern Cross Venture Partners, a Silicon Valley VC firm specializing in Australian innovation. He has been a director of 20 private sector boards in Australia and the US, including boards of two companies that were subsequently publicly listed. He is a member of the Innovation & Development and the People & Culture, Safety Committee.
    Mr Michael Kavanagh Chief Executive OfficerManaging Director Jul 2012
    Mr Kavanagh has 30 years of international commercial experience in the healthcare sector, Michael has a record of driving innovation, operational excellence, and sustainable growth across the medical device and pharmaceutical industries. Prior to joining Nanosonics, Michael served on the Executive Team of Cochlear Ltd for more than a decade as Senior Vice President of Global Marketing. He is a member of the Innovation & Development Committee.
    Ms Marie Elizabeth McDonald Non-Executive Director Oct 2016
    Ms McDonald brings with her a background in corporate and commercial law, having practiced for many years as a partner at Ashurst. Ms McDonald was Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia (2012 to 2013) and was a member of the Australian Takeovers Panel from 2001 to 2010. She is a member of the Risk committee and the Chair of the People & Culture, Safety Committee.
    Mr Steven Andrew Sargent Non-Executive DirectorNon-Executive Chairman Jul 2016
    Mr Sargent career included 22 years at General Electric, where he received multi-industry, international experience leading businesses in industries including healthcare, energy and financial services across the US, Europe and Asia Pacific. Mr Sargent has been a Non-Executive Director of Origin Energy Limited and is also a Non-Executive Director of Ramsay Healthcare Limited (since December 2021). Mr Sargent's unlisted board activities include Non-Executive Director of The Great Barrier Reef Foundation and Chairman of Origin Energy's philanthropic arm, The Origin Foundation. Mr Sargent was previously Chair of OFX Group Limited (2016 to 2022), and Nonexecutive Director of Veda Group Limited. He is a member of the Risk, Innovation & Development and the People & Culture, Safety Committee.
    Dr Tracey Leigh Batten Non-Executive Director Sep 2023
    Dr Batten has over 30 years of experience in the healthcare sector in non-executive and executive roles, and medical practitioner and clinical roles. Dr Batten was CEO of Imperial College Healthcare NHS Trust in the UK, St Vincent's Health Australia, Eastern Health and Dental Health Services Victoria. She is a member of the Risk and Innovation & Development Committee.
    Mr Gerard Dalbosco Non-Executive Director Jan 2025
    Mr Dalbosco had an executive career, most notably at EY, where he held senior leadership roles spanning multiple regions and functions, including Oceania Managing Partner and CEO, Asia Pacific Joint Deputy CEO, and Oceania Managing Partner - Transaction Advisory Services. Mr Dalbosco retired from the EY partnership in 2020. Mr Dalbosco's previous governance roles include Mercy Health & Aged Care, Berry Street Victoria and the Committee for Melbourne. Mr Dalbosco is currently a Non-Executive Director at Medibank Private Ltd and serves as Chair of Melbourne Archdiocese Catholic Schools. He is also Chair of the Gillespie Family Council & Gillespie Family Foundation (founders/owners of Bakers Delight). He is Chair of the Risk Committee and a member of the People & Culture, Safety Committee.
    Mr Matthew Carbines General CounselCompany Secretary May 2023
    -
    Jason Burriss Chief Financial Officer
    -
    Sunny Pillai Chief Information Officer
    -
    Kimberly Hill Chief Marketing Officer
    -
    Jonathan Burdach Chief Medical Affairs and Scientific Officer
    -
    Rod Lopez Chief Operating Officer and Regional President for Asia Pacific
    -
    Jodi Sampson Chief People & Culture Officer
    -
    Derek Minihane Chief Technology Officer
    -
    Matthew Carbines General Counsel and Company Secretary
    -
    Matthew Carbines General CounselCompany Secretary
    -
    Ronan Wright Regional President for Europe UK and Middle East
    -
    Ken Shaw Regional President for the United States Canada and Latin America
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 71,862,036 23.67%
    J P Morgan Nominees Australia Pty Limited 49,335,638 16.25%
    Citicorp Nominees Pty Limited 44,516,283 14.66%
    UBS Nominees Pty Ltd 13,266,641 4.37%
    BNP Paribas Noms Pty Ltd 13,157,234 4.33%
    BNP Paribas Nominees Pty Ltd <Agency Lending A/C> 10,995,075 3.62%
    Mr Maurie Stang 8,429,534 2.78%
    Mr Bernard Stang 6,882,564 2.27%
    Mr Steven Kenneth Kritzler 6,489,737 2.14%
    Australian Foundation Investment Company Limited 5,715,556 1.88%
    National Nominees Limited 3,834,135 1.26%
    HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 3,027,451 1.00%
    Dr Harry Hirschowitz 2,133,227 0.70%
    Mirrabooka Investments Limited 1,747,000 0.58%
    Bnp Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> 1,275,568 0.42%
    Mr Michael Kavanagh 1,256,723 0.41%
    HSBC Custody Nominees (Australia) Limited GSCO ECA 1,046,615 0.34%
    Mr Evan Philip Clucas & Ms Leanne Jane Weston <Kuranga Nursery Super A/C> 908,378 0.30%
    First Samuel Ltd Acn 086243567 <Anf Its Mda Clients A/C> 875,716 0.29%
    Powerwrap Limited <Escala Sma Trading A/C> 830,576 0.27%

    Profile

    since

    Note